Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: GB3038F4FA29EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Generalized Myasthenia Gravis (gMG) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Generalized Myasthenia Gravis (gMG) Understanding

The DelveInsight Generalized Myasthenia Gravis (gMG) epidemiology report gives a thorough understanding of the Generalized Myasthenia Gravis (gMG) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Generalized Myasthenia Gravis (gMG) in the US, Europe, and Japan. The report covers the detailed information of the Generalized Myasthenia Gravis (gMG) epidemiology scenario in seven major countries (US, EU5, and Japan).

Generalized Myasthenia Gravis (gMG) Epidemiology Perspective by DelveInsight

The Generalized Myasthenia Gravis (gMG) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Generalized Myasthenia Gravis (gMG) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Generalized Myasthenia Gravis (gMG) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Generalized Myasthenia Gravis (gMG) Detailed Epidemiology Segmentation

The Generalized Myasthenia Gravis (gMG) epidemiology covered in the report provides historical as well as forecasted Generalized Myasthenia Gravis (gMG) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Generalized Myasthenia Gravis (gMG) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Generalized Myasthenia Gravis (gMG) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Generalized Myasthenia Gravis (gMG) Epidemiology Report and Model provide an overview of the global trends of Generalized Myasthenia Gravis (gMG) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Generalized Myasthenia Gravis (gMG) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis (gMG)
• The report provides the segmentation of the Generalized Myasthenia Gravis (gMG) epidemiology

Report Highlights

• 11-year Forecast of Generalized Myasthenia Gravis (gMG) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Generalized Myasthenia Gravis (gMG)
• Cases of Generalized Myasthenia Gravis (gMG) by Mutation Types
• Generalized Myasthenia Gravis (gMG) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Generalized Myasthenia Gravis (gMG)?
• What are the key findings pertaining to the Generalized Myasthenia Gravis (gMG) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Generalized Myasthenia Gravis (gMG) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Generalized Myasthenia Gravis (gMG)?
• What are the currently available treatments of Generalized Myasthenia Gravis (gMG)?

Reasons to buy

The Generalized Myasthenia Gravis (gMG) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Generalized Myasthenia Gravis (gMG) market
• Quantify patient populations in the global Generalized Myasthenia Gravis (gMG) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Generalized Myasthenia Gravis (gMG) therapeutics in each of the markets covered
• Understand the magnitude of Generalized Myasthenia Gravis (gMG) population by its epidemiology
• The Generalized Myasthenia Gravis (gMG) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF GENERALIZED MYASTHENIA GRAVIS (GMG)

3. GENERALIZED MYASTHENIA GRAVIS (GMG): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Generalized Myasthenia Gravis (gMG) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Generalized Myasthenia Gravis (gMG) Treatment and Management
6.2. Generalized Myasthenia Gravis (gMG) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Generalized Myasthenia Gravis (gMG) Epidemiology in 7MM (2019-2032)
Table 2: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Generalized Myasthenia Gravis (gMG) Epidemiology in the United States (2019-2032)
Table 4: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Generalized Myasthenia Gravis (gMG) Epidemiology in Germany (2019-2032)
Table 6: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Generalized Myasthenia Gravis (gMG) Epidemiology in France (2019-2032)
Table 8: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Generalized Myasthenia Gravis (gMG) Epidemiology in Italy (2019-2032)
Table 10: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Generalized Myasthenia Gravis (gMG) Epidemiology in Spain (2019-2032)
Table 12: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Generalized Myasthenia Gravis (gMG) Epidemiology in the United Kingdom (2019-2032)
Table 14: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Generalized Myasthenia Gravis (gMG) Epidemiology in Japan (2019-2032)
Table 16: Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Generalized Myasthenia Gravis (gMG) Epidemiology in 7MM (2019-2032)
Figure 2 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Generalized Myasthenia Gravis (gMG) Epidemiology in the United States (2019-2032)
Figure 4 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Generalized Myasthenia Gravis (gMG) Epidemiology in Germany (2019-2032)
Figure 6 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Generalized Myasthenia Gravis (gMG) Epidemiology in France (2019-2032)
Figure 8 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Generalized Myasthenia Gravis (gMG) Epidemiology in Italy (2019-2032)
Figure 10 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Generalized Myasthenia Gravis (gMG) Epidemiology in Spain (2019-2032)
Figure 12 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Generalized Myasthenia Gravis (gMG) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Generalized Myasthenia Gravis (gMG) Epidemiology in Japan (2019-2032)
Figure 16 Generalized Myasthenia Gravis (gMG) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report